Simone Spreng

Summary

Affiliation: Berna Biotech Ltd
Country: Switzerland

Publications

  1. ncbi Plasmid maintenance systems suitable for GMO-based bacterial vaccines
    Simone Spreng
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018 Berne, Switzerland
    Vaccine 23:2060-5. 2005
  2. ncbi Rational design of Salmonella-based vaccination strategies
    Simone Spreng
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018 Berne, Switzerland
    Methods 38:133-43. 2006
  3. ncbi Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens
    Ivaylo Gentschev
    Berna Biotech Ltd, Berne, Switzerland
    Chemotherapy 53:177-80. 2007
  4. ncbi Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing protective listerial epitopes within a surface-exposed loop of the TolC-protein
    Simone Spreng
    Department of Microbiology, University of Wurzburg, D 97074, Wurzburg, Germany
    Vaccine 21:746-52. 2003
  5. ncbi Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain
    Ivaylo Gentschev
    Institut fur Medizinische Strahlenkunde und Zellforschung, University of Wurzburg, Versbacher Str 5, D 97078 Wurzburg, Germany
    Int J Med Microbiol 294:363-71. 2004
  6. ncbi Live attenuated bacteria as vectors to deliver plasmid DNA vaccines
    Guido Dietrich
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018, Berne, Switzerland
    Curr Opin Mol Ther 5:10-9. 2003
  7. ncbi Delivery of protein antigens and DNA by attenuated intracellular bacteria
    Ivaylo Gentschev
    Department of Microbiology, University of Wuerzburg, Germany
    Int J Med Microbiol 291:577-82. 2002
  8. ncbi Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae
    Didier Favre
    Berna Biotech Ltd, Department of Live Bacterial Vaccines, Rehhagstrasse 79, 3018 Bern, Switzerland
    Vaccine 24:4354-68. 2006
  9. ncbi Use of attenuated bacteria as delivery vectors for DNA vaccines
    Damini Daudel
    Berna Biotech AG, Rehhagstrasse 79, CH 3018 Berne, Switzerland
    Expert Rev Vaccines 6:97-110. 2007

Detail Information

Publications9

  1. ncbi Plasmid maintenance systems suitable for GMO-based bacterial vaccines
    Simone Spreng
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018 Berne, Switzerland
    Vaccine 23:2060-5. 2005
    ....
  2. ncbi Rational design of Salmonella-based vaccination strategies
    Simone Spreng
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018 Berne, Switzerland
    Methods 38:133-43. 2006
    ....
  3. ncbi Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens
    Ivaylo Gentschev
    Berna Biotech Ltd, Berne, Switzerland
    Chemotherapy 53:177-80. 2007
    ..Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria...
  4. ncbi Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing protective listerial epitopes within a surface-exposed loop of the TolC-protein
    Simone Spreng
    Department of Microbiology, University of Wurzburg, D 97074, Wurzburg, Germany
    Vaccine 21:746-52. 2003
    ..Mice immunized orally with this recombinant S. enteritidis live vaccine strain were protected against a lethal challenge with wildtype L. monocytogenes...
  5. ncbi Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain
    Ivaylo Gentschev
    Institut fur Medizinische Strahlenkunde und Zellforschung, University of Wurzburg, Versbacher Str 5, D 97078 Wurzburg, Germany
    Int J Med Microbiol 294:363-71. 2004
    ..Therefore, the combination of the hemolysin secretion system and S. typhi Ty21a could form the basis for a new generation of live bacterial vaccines...
  6. ncbi Live attenuated bacteria as vectors to deliver plasmid DNA vaccines
    Guido Dietrich
    Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH 3018, Berne, Switzerland
    Curr Opin Mol Ther 5:10-9. 2003
    ..The next step should be the clinical assessment of the safety, immunogenicity and efficacy of DNA vaccine delivery by live bacterial vaccines...
  7. ncbi Delivery of protein antigens and DNA by attenuated intracellular bacteria
    Ivaylo Gentschev
    Department of Microbiology, University of Wuerzburg, Germany
    Int J Med Microbiol 291:577-82. 2002
    ....
  8. ncbi Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae
    Didier Favre
    Berna Biotech Ltd, Department of Live Bacterial Vaccines, Rehhagstrasse 79, 3018 Bern, Switzerland
    Vaccine 24:4354-68. 2006
    ..cholerae. Finally, co-expression of two or three CFs in the same strain was efficient even under the control of one single regulator gene...
  9. ncbi Use of attenuated bacteria as delivery vectors for DNA vaccines
    Damini Daudel
    Berna Biotech AG, Rehhagstrasse 79, CH 3018 Berne, Switzerland
    Expert Rev Vaccines 6:97-110. 2007
    ..The clinical assessment of the safety, immunogenicity and efficacy of these candidate strains will be the next challenging step towards live bacterial DNA vaccines...